Brooks Laboratories to demerge manufacturing business into Abridge Speciality Ltd.
Brooks Laboratories approved a demerger of its manufacturing business into Abridge Speciality Limited. The manufacturing division had a turnover of ₹8,287.26 lakhs in FY26, 96.66% of the total. Shareholders will receive a 1:1 share entitlement in the resulting company. Listing of the new entity is expected in approximately 16 months.
A demerger of this scale, involving the majority of the company's turnover and leading to the creation of two distinct listed entities, will have a significant impact on the company's structure, operations, and shareholder value.
The demerger is expected to create focused business platforms, enhance strategic flexibility, and potentially unlock shareholder value, which are positive outcomes for the company.
Brooks Laboratories Limited announced its Board of Directors has approved a Scheme of Arrangement for the demerger of its Manufacturing Business into its wholly-owned subsidiary, Abridge Speciality Limited. This scheme, under Sections 230-232 of the Companies Act, 2013, is subject to approvals from stock exchanges, SEBI, NCLT, and shareholders. The demerged undertaking includes the manufacturing operations at the Baddi facility, along with associated sales, exports, loan-licensing, and contract manufacturing. For the financial year ended March 31, 2026, the turnover attributable to the demerged undertaking was ₹8,287.26 lakhs, representing approximately 96.66% of the company's total turnover.
The rationale behind the demerger includes creating focused business platforms with clearer accountability, enabling independent growth strategies, operational and financial clarity, and enhancing stakeholder value. Upon effectiveness, Abridge Speciality Limited will be renamed Brooks Laboratories Limited, and the current Brooks Laboratories Limited will be renamed Xuri Lifesciences Limited.
Shareholders will receive one equity share of Abridge Speciality Limited for every one equity share held in Brooks Laboratories Limited. The Resulting Company, Abridge Speciality Limited, is expected to seek listing on BSE and NSE. The overall indicative timeline for the scheme implementation, including listing, is approximately 16 months. The Board meeting commenced at 4:00 PM IST and concluded at 5:30 PM IST on October 14, 2026.
What to do with a filing like this
Brooks Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under demerger. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Brooks Laboratories Limited. Read the original for the full detail.